HUMAN GENOME SCIENCES AND GLAXOSMITHKLINE ANNOUNCE FDA EXTENSION OF BENLYSTA® PDUFA TARGET DATE TO MARCH 10, 2011

Printer-friendly versionPDF version

ROCKVILLE, Maryland, and LONDON, UK – December 3, 2010– Human Genome Sciences, Inc. (Nasdaq: HGSI) and GlaxoSmithKline PLC (GSK) today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) target date for its priority review of the Biologics License Application (BLA) for BENLYSTA® (belimumab) as a potential treatment for systemic lupus erythematosus (SLE) from December 9, 2010 to March 10, 2011.

After the FDA Arthritis Advisory Committee met on November 16, 2010 to consider the BENLYSTA BLA, the FDA requested some additional information from HGS, which has been submitted.

Belimumab is an investigational drug and the first in a new class of drugs called BLyS-specific inhibitors. HGS and GSK are developing belimumab under a definitive co-development and co-commercialization agreement entered into in 2006.

GlaxoSmithKline– one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visitwww.gsk.com.GSK Biopharm R&Dis employing novel approaches to harness the therapeutic potential of biopharmaceuticals for the benefit of patients with serious autoimmune disease.

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs. For more information about HGS, please visit the Company’s web site at www.hgsi.com. Health professionals and patients interested in clinical trials of HGS products may inquire via e-mail to

This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

or by calling HGS at (877) 822-8472. HGS, Human Genome Sciences, and BENLYSTA are trademarks of Human Genome Sciences, Inc. Other trademarks referenced are the property of their respective owners.

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are based on Human Genome Sciences’ current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ materially from these forward-looking statements because of Human Genome Sciences’ unproven business model, its dependence on new technologies, the uncertainty and timing of clinical trials and regulatory approvals, Human Genome Sciences’ ability to develop and commercialize products, its dependence on collaborators for services and revenue, its substantial indebtedness and lease obligations, its changing requirements and costs associated with facilities, intense competition, the uncertainty of patent and intellectual property protection, Human Genome Sciences’ dependence on key management and key suppliers, the uncertainty of regulation of products, the impact of future alliances or transactions and other risks described in the Company’s filings with the SEC. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today’s date. Human Genome Sciences undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.

Under the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK's operations are described under 'Risk Factors' in the ‘Business Review’ in GSK's Annual Report on Form 20-F for 2009.

###

HGS Contacts:

Media

Jerry Parrott
Vice President, Corporate Communications
301-315-2777

Investors

Claudine Prowse, Ph.D.
Executive Director, Investor Relations
301-315-1785

Peter Vozzo
Senior Director, Investor Relations
301-251-6003

GSK CONTACTS:

U.K. Media Inquiries --

David Mawdsley, (020) 8047-5502
Claire Brough, (020) 8047-5502
Stephen Rea, (020) 8047-5502
Alexandra Harrison, (020) 8047-5502
Jo Revill, (020) 8047-5502

U.S. Media Inquiries --

Holly Russell, 919-483-2839
Mary Anne Rhyne, 919-483-2839

European Analyst/Investor Inquiries

Sally Ferguson, (020) 8047-5543
Gary Davies, (020) 8047-5503

U.S. Analyst/Investor Inquiries –

Tom Curry, 215-751-5419
Jen Hill Baxter, 215-751-7002

News Source : HUMAN GENOME SCIENCES AND GLAXOSMITHKLINE ANNOUNCE FDA EXTENSION OF BENLYSTA® PDUFA TARGET DATE TO MARCH 10, 2011